Biotech venture debt is often used by companies that expect to repay the loan through future equity funding, licensing or partnership income, product sales, or other strategic deals rather than current revenue. Because biotech companies often face long development timelines and uncertain outcomes, lenders structure these facilities to provide needed capital while managing clinical, regulatory, and repayment risks.
This article is for biotech founders looking to understand venture debt, including its financing structure, milestone requirements, lender expectations, and key risks.
Why Biotech Startups Choose Venture Debt
Therapeutics companies typically develop products through several stages over a multi-year period, beginning with preclinical research and progressing, where applicable, through Phase 1, Phase 2, and Phase 3 clinical trials, regulatory review, and commercialization.
For many therapeutics companies, meaningful product revenue does not arise until late in this process, although licensing payments, partnership proceeds, grant funding, or research revenue may occur earlier. Companies therefore often rely on equity financing to fund development, which can dilute existing shareholders, particularly when capital is raised before important clinical data are released.
Venture debt provides additional financing without immediate equity dilution, though warrants may cause future dilution.
Core advantages include:
- A facility typically prolongs the operation of a company by months, occasionally enabling it to reach key milestones, such as an IND submission and effectiveness, Phase 2 results, or a pivotal-trial readout before securing additional capital.
- Warrants may result in less dilution than an equivalent equity raise, although the actual dilution depends on the warrant size, exercise price, capitalization table, and future financing events.
- Companies may use the capital for product-development expenses, specialized equipment, working capital, or as a bridge between equity rounds and strategic events such as partnerships or acquisitions.
Typical Financing Structure for Biotech Venture Debt
Venture debt usually has a 36–48 month term, but longer terms can be available for companies further along in their development. The facility size is assessed individually and may reach 20–35% of the latest equity round. Lenders also consider cash burn, runway, investor support, milestones, development stage, and expected repayment sources. Key features may include:
- Staged funding: The loan is often released in stages, with additional funds becoming available as the company meets agreed-upon clinical, regulatory, financing, or liquidity milestones.
- Repayment terms: The loan may include 12 to 18 months of interest-only payments. After that, the company begins repaying principal and interest on an agreed schedule. Some deals may also include PIK interest or a final payment.
- Pricing and fees: Interest is typically based on a floating rate, such as SOFR + a 6–9% spread, but some lenders may also offer fixed rates. Based on a company’s stage of development and risk profile, the interest rate generally ranges from 8–15%. Upfront fees and end-of-term charges can contribute to the total cost of the loan.
- Warrants: They give lenders an opportunity to benefit if the company grows. They typically cover 5% to 15% of the loan amount, depending on the deal structure and risk profile.
- Security and covenants: Lenders might impose certain obligations on a company, such as maintaining enough cash, periodically producing financial reports, using collateral for secured assets, restricting additional debt, or limiting major transactions.
Early-stage biotech companies may not have enough revenue for traditional revenue covenants to be useful. Lenders may instead focus on milestones, cash reserves, and liquidity. The figures are indicative and can vary by lender and borrower.
How Milestones Shape Biotech Venture Debt
Clearly defined milestones reduce lenders’ risk and unlock funding tranches. These milestones can range from an IND submission to clinical trial initiation, patient recruitment phase, release of clinical data, regulatory approval, capital raise, or alliance. The company may also need to have certain financial covenants in place, which will require maintaining a sufficient amount of cash or liquidity.
Financing documents must clearly specify how each milestone will be measured, its achievement deadline, the type of proof the company must provide, as well as the consequences of delaying or failing to achieve the milestone. The agreement may also include a cure period or procedures for obtaining a waiver or amendment. In some cases, it may provide relief for events outside the company’s reasonable control.
Missed milestones: A loan provider could decide to halt the disbursement of funds and, depending on the terms, declare a default if a specific target is not achieved before the due date. The loan contract should specify any grace periods or waivers and whether a missed milestone immediately triggers a default or simply halts further financing. Generally, the loan conditions requiring a certain level of cash and liquidity continue to be binding until the end of the loan period.
Risks and Trade-Offs
Venture debt entails fixed payments regardless of the company’s clinical trial results, even if the trial is delayed or fails. In addition, interest, upfront fees, end-of-term charges, prepayment penalties, and warrant dilution are the main elements that add to the costs. The costs could keep growing if the company raises equity at a lower valuation or does not achieve the partnerships, licensing, or financing proceeds it aims for.
Loan agreements in many cases place restrictions on additional secured or unsecured borrowing, the creation of new liens, the sale of assets, acquisitions, the issuance of dividends, the licensing of or entering into significant partnership agreements, and certain changes in controlling interest without the lender’s permission. These types of restrictions can lead to a loss of strategic flexibility.
Companies need to model their repayment capacity in favorable scenarios as well as adverse ones. Clinical delays, lower-than-expected financing proceeds, a loss of investor support, and failure to achieve key milestones should be included in this analysis.
Lender Due Diligence
Lenders look at several things before approving venture debt. These include the company’s intellectual property, existing debt, licensing agreements, expected cash flow, clinical trial costs, regulatory updates, insurance, and other funding sources. They also consider the investors, management team, products close to launch, and clinical trial plans. Companies with several reliable funding sources may get better terms than those that depend on the success of one product or clinical trial.
Problems such as incomplete IP assignments, unresolved regulatory issues, or restrictive third-party agreements may delay financing or result in additional conditions.
Negotiating the Facility
Companies should consider the facility in terms of its overall economic cost and operational limitations rather than merely comparing interest rates. Some key areas are:
- The total committed amount and the portion available immediately.
- Interest, fees, warrants, and prepayment costs.
- The interest-only period and repayment schedule.
- Security arrangements and permitted liens.
- Financial reporting and compliance requirements.
- Restrictions on future borrowing and corporate transactions.
- Lender rights following a default or material adverse event.
The company should also verify whether the facility is fully committed and when the lender can cancel or terminate any undrawn portion, such as after the availability period expires, following a default, or upon another specified termination event.
Frequently Asked Questions About Biotech Venture Debt
Below are answers to frequently asked questions about biotech venture debt:
Can Venture Debt Be Converted Into Equity?
Typically, venture debt remains a loan obligation and does not automatically convert into equity. Any conversion feature is subject to the terms of the specific financing agreement. It should not be assumed that such a feature is included in a standard venture debt facility.
Does Venture Debt Affect a Company’s Valuation?
Venture debt has no direct effect on a company’s valuation. Nonetheless, the amount of outstanding debt and other related financial obligations may influence how investors view the company’s financial position and the portion of the value available to existing shareholders.
Does Venture Debt Require a Personal Guarantee From Founders?
Not necessarily. Venture debt is usually determined based on the company’s financial health, assets, investors, and performance, but not the founder’s personal credit. Some lenders might ask for a personal guarantee, though.
How Long Does It Take to Close a Biotech Venture Debt Facility?
The timeframe largely depends on the lender, the nature of the transaction, the required due diligence, the level of documentation, and the number of internal approvals needed. A simple loan agreement can close relatively quickly, while deals involving complicated security packages, several parties, and existing lenders can take longer.
How is venture debt different from royalty-based or revenue-based financing?
Venture debt refers to term loans that require repayment of both the principal and interest, typically on a fixed schedule. On the other hand, royalty-based or revenue-based financing ties repayments to the company’s revenue, so they fluctuate with the company’s performance.
Does venture debt affect our ability to raise the next equity round?
Venture debt may affect your ability to raise equity if the debt causes financial stress or comes with restrictive terms. On the other hand, well-managed venture debt can help extend your runway and give you more time to raise funds.
A Strategic Financing Option for Biotech Startups
Venture debt may be very beneficial to a biotech startup’s fundraising plan if the company has a well-defined strategy for handling repayment and future capital requirements. Rather than concentrating solely on how much funding the company can obtain through venture debt, entrepreneurs should consider the total cost, flexibility, and long-term implications of taking on the facility.
Cheqly’s venture debt solution offers eligible startups an alternative source of growth capital, helping them access funding while maintaining greater flexibility in how they structure their overall financing strategy.
Ready to explore venture debt as part of your biotech startup’s funding strategy? Check your eligibility and explore Cheqly’s financing solutions.